Mucositis temsirolimus

Temsirolimus (Torisel Kit) [mTOR Inhibitor] Uses Advanced RCC Action mTOR inhibitor Dose 25 mg IV over 30-60 min x 1 wk continue until tox or progression pre med w/ 25-50 mg Benadryl 30 min before Caution [D, -] w/ CYP3A4 inhib/inducers (Table VI-8), avoid grapefruit juice, vaccines, immediately postop Contra None Disp IV SE Hypersensitivity Rxn, rash, asthenia, mucositis, N, edema, anorexia, poor wound healing, bowel perfusion EMS May T glucose OD May cause NA, abd pain, HA, confusion, melana, and Szs symptomatic and supportive... 

A study of seven children taking a combination of temsirolimus and VPA found that the maximum tolerated dose of temsirolimus is considerably lower when given with VPA than when it is given as a single agent mucositis was the major dose-limiting toxicity [192 ]. 

In a multicenter, open-label, phase 2 study in 19 cancer centres in the United States, patients with bone or soft-tissue sarcoma were treated with weekly cixutumumab (6mg/kg, intravenous) and temsirolimus (25 mg, intravenous) in 6-week cycles. There were 2546 adverse events reported during the study, 214 (8%) of which were grade 3-4. The most common grade 3-4 toxicities were lymphopenia (14%), oral mucositis (11%), thrombocytopenia (11%), hyperglycaemia (10%), hypophosphataemia (9%) and anaemia... 

---